The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes

Woo, Vincent; Connelly, Kim A.; Lin, Peter; McFarlane, Philip A.

doi:10.1080/03007995.2019.1576479

Cited by 15 publications

(14 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the future, target excavation and development of new drugs related to inflammation, endothelial dysfunction, oxidative stress, and other pathophysiological changes in CRS are of great value and prospect (15). ARNI and SGLT-2i have shown tremendous benefits to both the heart and kidneys in patients with chronic diseases, which especially demonstrates the pioneering concept of cardiorenal co-treatment (16,17). As for the initial precipitant of the vicious circle of type 6 CRS, chronic systemic diseases should be well-controlled with respect to indispensability, such as hypertension, diabetes mellitus, obesity, etc.…”

Section: Treatment Of Type 6 Crsmentioning

confidence: 99%

Chronic Secondary Cardiorenal Syndrome: The Sixth Innovative Subtype

Zhang

Yue

Yang

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Section: Treatment Of Type 6 Crsmentioning

confidence: 99%

Chronic Secondary Cardiorenal Syndrome: The Sixth Innovative Subtype

Zhang

Yue

Yang

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

“…Особенности сахароснижающей терапии при остром коронарном синдроме у пациентов с сахарным диабетом второго типа сообщили, что эмпаглифлозин может ослаблять перикоронарный артериальный фиброз и утолще ние коронарных артерий [22]. Снижение фиброза миокарда связано с ослаблением экспрессии глюко кортикоидрегулируемой киназы1, которая являет ся частью профиброзного сигнального пути, а также эпителиального натриевого канала (рис.…”

Section: предполагаемые механизмы кардиопротекции ингибиторами натрийглюкозного котранспортера второго типаunclassified

“…Важным метаболическим показателем для прогноза исходов ОКС можно считать глюкозу плазмы крови, определяемую у больного в первые минуты/часы от развития индексного события [38; 39]. Эффективность и безопасность аГПП1, иНГЛТ2 и иДПП4 при ОКС изучается [17][18][19][20][21][22][23].…”

Section: заключениеunclassified

Peculiarities of hypoglycaemic therapy in acute coronary syndrome in patients with type 2 diabetes mellitus

Bondareva¹,

Kovaleva²,

Lifshic³

2021

PKiK

View full text Add to dashboard Cite

This study assessed the features of the course of acute coronary syndrome in patients with diabetic neuropathy. Additionally, the role of antihyperglycaemic therapy as a cardio protection factor in this syndrome was determined by analysing the available literature data and clinical guidelines. Various antihyperglycaemic drug groups demonstrate possible molecular mechanisms of protection against ischemic cardiomyocytes. Cardiovascular disease treatment for patients with type 2 diabetes mellitus is rapidly developing. However, many aspects, including the exact mechanisms of the cardio protective action of antihyperglycaemic drugs, the presence of an additional positive effect of antihyperglycaemic drugs for patients with other diseases (e.g. kidney disease and chronic heart failure), and possible primary prevention of cardiovascular events in patients with type 2 diabetes, remain unclear.Received 11 September 2020. Revised 16 January 2021. Accepted 10 February 2021.Funding: The study did not have sponsorship.Conflict of interest: Authors declare no conflict of interest.

show abstract

“…Efek antihiperglikemiknya secara klinis mirip dengan penurun glukosa darah lainnya. Namun, daya tahan efeknya lebih besar dari pada sulfonilurea, dan lebih efektif pada individu dengan HbA1c> 8,0%, daripada DPP-4 inhibitor (Woo et al, 2019).…”

Section: Hasilunclassified

“…Efek natriuretik dan diuretik dari SGLT-2 inhibitor kemungkinan besar bertanggung jawab atas efek antihipertensi (Woo et al, 2019).…”

Section: Pembahasanunclassified

Effect of SGLT-2 Inhibitor Therapy on Cardiovascular Health in Diabetes Mellitus Patients

Destiana

2019

jppp

View full text Add to dashboard Cite

Penyakit kardiovaskular telah menjadi penyebab utama mortalitas dan morbiditas pada pasien dengan diabetes melitus tipe 2. Faktor utama peningkatan risiko penyakit kardiovaskular antara lain hiperglikemia kronis, penurunan sensitivitas insulin, adipositas viseral, dan khususnya komorbiditas hipertensi dan peningkatan arterial stiffness. Sementara itu, sodium-glukosa cotransporter-2 inhibitor, kategori baru dalam terapi diabetes diketahui mengurangi glukosa darah pada pasien dengan meningkatkan glikosuria melalui penghambatan reabsorpsi glukosa urin. Terapi tersebut juga menghasilkan diuresis osmotik yang diinduksi glukosa, penurunan berat badan, dan penurunan tekanan darah. Tujuan dari literature review ini adalah untuk mengetahui efek sodium-glukosa co-transporter-2 inhibitor terhadap kesehatan kardiovaskular pada pasien diabetes mellitus. Penelitian ini merupakan literature review yang melibatkan sumber pustaka sebanyak 20 pustaka yang berasal dari 3 jurnal nasional dan 17 jurnal internasional dengan kata kunci yang digunakan antara lain diabetes mellitus,cardiovascular dan SGLT-2 inhibitor. Beberapa penelitian secara signifikan menunjukkan efek SGLT-2 inhibitor pada kesehatan kardiovaskular, yang terlihat dengan adanya penurunan mortalitas dan rawat inap gagal jantung, tekanan darah dan renal outcome yang lebih baik, peningkatan fungsi jantung pada kardiomiopati diabetes dan iskemik miokard.

show abstract

The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes

Abstract: McFarlane (2019) The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes,

Cited by 15 publications

References 106 publications

Chronic Secondary Cardiorenal Syndrome: The Sixth Innovative Subtype

Chronic Secondary Cardiorenal Syndrome: The Sixth Innovative Subtype

Peculiarities of hypoglycaemic therapy in acute coronary syndrome in patients with type 2 diabetes mellitus

Effect of SGLT-2 Inhibitor Therapy on Cardiovascular Health in Diabetes Mellitus Patients

Contact Info

Product

Resources

About